In-vitro  ||| S:0 E:9 ||| JJ
evaluation  ||| S:9 E:20 ||| NN
of  ||| S:20 E:23 ||| IN
the  ||| S:23 E:27 ||| DT
effect  ||| S:27 E:34 ||| NN
of  ||| S:34 E:37 ||| IN
polymer  ||| S:37 E:45 ||| JJ
structure  ||| S:45 E:55 ||| NN
on  ||| S:55 E:58 ||| IN
uptake  ||| S:58 E:65 ||| NN
of  ||| S:65 E:68 ||| IN
novel  ||| S:68 E:74 ||| JJ
polymer-insulin  ||| S:74 E:90 ||| JJ
polyelectrolyte  ||| S:90 E:106 ||| JJ
complexes  ||| S:106 E:116 ||| NNS
by  ||| S:116 E:119 ||| IN
human  ||| S:119 E:125 ||| JJ
epithelial  ||| S:125 E:136 ||| JJ
cells  ||| S:136 E:142 ||| NNS
The  ||| S:142 E:146 ||| DT
biocompatibility  ||| S:146 E:163 ||| NN
and  ||| S:163 E:167 ||| CC
cellular  ||| S:167 E:176 ||| JJ
uptake  ||| S:176 E:183 ||| NN
of  ||| S:183 E:186 ||| IN
polymer ||| S:186 E:193 ||| NN
,  ||| S:193 E:195 ||| ,
insulin  ||| S:195 E:203 ||| NN
polyelectrolyte  ||| S:203 E:219 ||| NN
complexes  ||| S:219 E:229 ||| NNS
( ||| S:229 E:230 ||| -LRB-
PECs ||| S:230 E:234 ||| NNP
)  ||| S:234 E:236 ||| -RRB-
prepared  ||| S:236 E:245 ||| VBN
using  ||| S:245 E:251 ||| VBG
polyallylamine-based  ||| S:251 E:272 ||| JJ
polymers  ||| S:272 E:281 ||| NNS
was  ||| S:281 E:285 ||| VBD
evaluated  ||| S:285 E:295 ||| VBN
in-vitro  ||| S:295 E:304 ||| JJ
using  ||| S:304 E:310 ||| VBG
Caco-2  ||| S:310 E:317 ||| CD
cell  ||| S:317 E:322 ||| NN
monolayers  ||| S:322 E:333 ||| NN
as  ||| S:333 E:336 ||| IN
a  ||| S:336 E:338 ||| DT
predictive  ||| S:338 E:349 ||| JJ
model  ||| S:349 E:355 ||| NN
for  ||| S:355 E:359 ||| IN
human  ||| S:359 E:365 ||| JJ
small  ||| S:365 E:371 ||| JJ
intestinal  ||| S:371 E:382 ||| JJ
epithelial  ||| S:382 E:393 ||| JJ
cells ||| S:393 E:398 ||| NNS
.  ||| S:398 E:400 ||| .
Poly ||| S:400 E:404 ||| NNP
( ||| S:404 E:405 ||| -LRB-
allyl  ||| S:405 E:411 ||| FW
amine ||| S:411 E:416 ||| FW
)  ||| S:416 E:418 ||| -RRB-
( ||| S:418 E:419 ||| -LRB-
PAA ||| S:419 E:422 ||| NNP
)  ||| S:422 E:424 ||| -RRB-
and  ||| S:424 E:428 ||| CC
Quaternised  ||| S:428 E:440 ||| NNP
PAA  ||| S:440 E:444 ||| NNP
( ||| S:444 E:445 ||| -LRB-
QPAA ||| S:445 E:449 ||| NNP
)  ||| S:449 E:451 ||| -RRB-
were  ||| S:451 E:456 ||| VBD
thiolated  ||| S:456 E:466 ||| VBN
using  ||| S:466 E:472 ||| VBG
either  ||| S:472 E:479 ||| DT
carbodiimide  ||| S:479 E:492 ||| JJ
mediated  ||| S:492 E:501 ||| JJ
conjugation  ||| S:501 E:513 ||| NN
to  ||| S:513 E:516 ||| TO
N-acetylcysteine  ||| S:516 E:533 ||| NNP
( ||| S:533 E:534 ||| -LRB-
NAC ||| S:534 E:537 ||| NNP
)  ||| S:537 E:539 ||| -RRB-
or  ||| S:539 E:542 ||| CC
reaction  ||| S:542 E:551 ||| NN
with  ||| S:551 E:556 ||| IN
2-iminothiolane  ||| S:556 E:572 ||| CD
hydrochloride  ||| S:572 E:586 ||| NNS
yielding  ||| S:586 E:595 ||| VBG
their  ||| S:595 E:601 ||| PRP$
NAC  ||| S:601 E:605 ||| NNP
and  ||| S:605 E:609 ||| CC
4-thiobutylamidine  ||| S:609 E:628 ||| NNP
( ||| S:628 E:629 ||| -LRB-
TBA ||| S:629 E:632 ||| NNP
)  ||| S:632 E:634 ||| -RRB-
conjugates ||| S:634 E:644 ||| NN
,  ||| S:644 E:646 ||| ,
respectively ||| S:646 E:658 ||| RB
.  ||| S:658 E:660 ||| .
The  ||| S:660 E:664 ||| DT
effect  ||| S:664 E:671 ||| NN
of  ||| S:671 E:674 ||| IN
polymer  ||| S:674 E:682 ||| JJ
quaternisation  ||| S:682 E:697 ||| NN
and ||| S:697 E:700 ||| CC
/ ||| S:700 E:701 ||| NNP
or  ||| S:701 E:704 ||| CC
thiolation  ||| S:704 E:715 ||| NN
on  ||| S:715 E:718 ||| IN
the  ||| S:718 E:722 ||| DT
IC50  ||| S:722 E:727 ||| NN
of  ||| S:727 E:730 ||| IN
PAA  ||| S:730 E:734 ||| NNP
was  ||| S:734 E:738 ||| VBD
determined  ||| S:738 E:749 ||| VBN
by  ||| S:749 E:752 ||| IN
3- ||| S:752 E:754 ||| NNP
( ||| S:754 E:755 ||| -LRB-
4,5-dimethylthiazol-2-yl ||| S:755 E:779 ||| NNP
) ||| S:779 E:780 ||| -RRB-
-2,5-diphenyltetrazolium  ||| S:780 E:805 ||| FW
bromide  ||| S:805 E:813 ||| FW
( ||| S:813 E:814 ||| -LRB-
MTT ||| S:814 E:817 ||| NNP
)  ||| S:817 E:819 ||| -RRB-
assay  ||| S:819 E:825 ||| VBZ
carried  ||| S:825 E:833 ||| VBN
out  ||| S:833 E:837 ||| RP
on  ||| S:837 E:840 ||| IN
Caco-2  ||| S:840 E:847 ||| CD
cells  ||| S:847 E:853 ||| NNS
( ||| S:853 E:854 ||| -LRB-
with  ||| S:854 E:859 ||| IN
and  ||| S:859 E:863 ||| CC
without  ||| S:863 E:871 ||| IN
a  ||| S:871 E:873 ||| DT
24  ||| S:873 E:876 ||| CD
h  ||| S:876 E:878 ||| JJ
recovery  ||| S:878 E:887 ||| NN
period  ||| S:887 E:894 ||| NN
after  ||| S:894 E:900 ||| IN
samples  ||| S:900 E:908 ||| NNS
were  ||| S:908 E:913 ||| VBD
removed ||| S:913 E:920 ||| VBN
) ||| S:920 E:921 ||| -RRB-
.  ||| S:921 E:923 ||| .
Uptake  ||| S:923 E:930 ||| NNP
of  ||| S:930 E:933 ||| IN
PECs  ||| S:933 E:938 ||| JJ
by  ||| S:938 E:941 ||| IN
Caco-2  ||| S:941 E:948 ||| CD
cells  ||| S:948 E:954 ||| NNS
was  ||| S:954 E:958 ||| VBD
monitored  ||| S:958 E:968 ||| VBN
by  ||| S:968 E:971 ||| IN
microscopy  ||| S:971 E:982 ||| FW
using  ||| S:982 E:988 ||| FW
fluorescein  ||| S:988 E:1000 ||| FW
isothiocyanate  ||| S:1000 E:1015 ||| FW
( ||| S:1015 E:1016 ||| -LRB-
FITC ||| S:1016 E:1020 ||| NNP
)  ||| S:1020 E:1022 ||| -RRB-
labelled  ||| S:1022 E:1031 ||| JJ
insulin  ||| S:1031 E:1039 ||| NN
and  ||| S:1039 E:1043 ||| CC
rhodamine-labelled  ||| S:1043 E:1062 ||| JJ
polymers  ||| S:1062 E:1071 ||| NNS
at  ||| S:1071 E:1074 ||| IN
polymer ||| S:1074 E:1081 ||| NNS
: ||| S:1081 E:1082 ||| :
insulin  ||| S:1082 E:1090 ||| NN
ratios  ||| S:1090 E:1097 ||| NNS
( ||| S:1097 E:1098 ||| -LRB-
4 ||| S:1098 E:1099 ||| LS
: ||| S:1099 E:1100 ||| :
5 ||| S:1100 E:1101 ||| LS
)  ||| S:1101 E:1103 ||| -RRB-
after  ||| S:1103 E:1109 ||| IN
0.5 ||| S:1109 E:1112 ||| CD
,  ||| S:1112 E:1114 ||| ,
1 ||| S:1114 E:1115 ||| CD
,  ||| S:1115 E:1117 ||| ,
2  ||| S:1117 E:1119 ||| CD
and  ||| S:1119 E:1123 ||| CC
4  ||| S:1123 E:1125 ||| CD
h  ||| S:1125 E:1127 ||| JJ
incubation  ||| S:1127 E:1138 ||| NN
in  ||| S:1138 E:1141 ||| IN
growth  ||| S:1141 E:1148 ||| NN
media  ||| S:1148 E:1154 ||| NNS
( ||| S:1154 E:1155 ||| -LRB-
Â±calcium ||| S:1155 E:1163 ||| NNP
)  ||| S:1163 E:1165 ||| -RRB-
and  ||| S:1165 E:1169 ||| CC
following  ||| S:1169 E:1179 ||| VBG
pre-incubation  ||| S:1179 E:1194 ||| JJ
with  ||| S:1194 E:1199 ||| IN
insulin ||| S:1199 E:1206 ||| NN
.  ||| S:1206 E:1208 ||| .
MTT  ||| S:1208 E:1212 ||| NNP
results  ||| S:1212 E:1220 ||| NNS
indicated  ||| S:1220 E:1230 ||| VBD
that  ||| S:1230 E:1235 ||| DT
quaternisation  ||| S:1235 E:1250 ||| NN
of  ||| S:1250 E:1253 ||| IN
PAA  ||| S:1253 E:1257 ||| NNP
was  ||| S:1257 E:1261 ||| VBD
associated  ||| S:1261 E:1272 ||| VBN
with  ||| S:1272 E:1277 ||| IN
an  ||| S:1277 E:1280 ||| DT
improvement  ||| S:1280 E:1292 ||| NN
in  ||| S:1292 E:1295 ||| IN
IC50  ||| S:1295 E:1300 ||| CD
values ||| S:1300 E:1306 ||| NNS
;  ||| S:1306 E:1308 ||| :
cells  ||| S:1308 E:1314 ||| NNS
treated  ||| S:1314 E:1322 ||| VBN
with  ||| S:1322 E:1327 ||| IN
QPAA  ||| S:1327 E:1332 ||| NNP
( ||| S:1332 E:1333 ||| -LRB-
0.001-4  ||| S:1333 E:1341 ||| FW
mg  ||| S:1341 E:1344 ||| FW
mL ||| S:1344 E:1346 ||| FW
( ||| S:1346 E:1347 ||| -LRB-
-1 ||| S:1347 E:1349 ||| NNP
) ||| S:1349 E:1350 ||| -RRB-
)  ||| S:1350 E:1352 ||| -RRB-
showed  ||| S:1352 E:1359 ||| VBD
no  ||| S:1359 E:1362 ||| DT
signs  ||| S:1362 E:1368 ||| NNS
of  ||| S:1368 E:1371 ||| IN
toxicity  ||| S:1371 E:1380 ||| NNS
following  ||| S:1380 E:1390 ||| VBG
a  ||| S:1390 E:1392 ||| DT
24  ||| S:1392 E:1395 ||| CD
h  ||| S:1395 E:1397 ||| JJ
cell  ||| S:1397 E:1402 ||| NN
recovery  ||| S:1402 E:1411 ||| NN
period ||| S:1411 E:1417 ||| NN
,  ||| S:1417 E:1419 ||| ,
while  ||| S:1419 E:1425 ||| IN
thiolation  ||| S:1425 E:1436 ||| NN
of  ||| S:1436 E:1439 ||| IN
QPAA  ||| S:1439 E:1444 ||| NNP
resulted  ||| S:1444 E:1453 ||| VBD
in  ||| S:1453 E:1456 ||| IN
a  ||| S:1456 E:1458 ||| DT
decrease  ||| S:1458 E:1467 ||| NN
in  ||| S:1467 E:1470 ||| IN
the  ||| S:1470 E:1474 ||| DT
IC50 ||| S:1474 E:1478 ||| NN
.  ||| S:1478 E:1480 ||| .
Cellular  ||| S:1480 E:1489 ||| JJ
uptake  ||| S:1489 E:1496 ||| JJ
studies  ||| S:1496 E:1504 ||| NNS
showed  ||| S:1504 E:1511 ||| VBD
that  ||| S:1511 E:1516 ||| IN
within  ||| S:1516 E:1523 ||| IN
2-4  ||| S:1523 E:1527 ||| CD
h ||| S:1527 E:1528 ||| NN
,  ||| S:1528 E:1530 ||| ,
QPAA  ||| S:1530 E:1535 ||| NNP
and  ||| S:1535 E:1539 ||| CC
QPAA-TBA  ||| S:1539 E:1548 ||| JJ
insulin  ||| S:1548 E:1556 ||| NN
PECs  ||| S:1556 E:1561 ||| NN
were  ||| S:1561 E:1566 ||| VBD
taken  ||| S:1566 E:1572 ||| VBN
up  ||| S:1572 E:1575 ||| RP
intracellularly ||| S:1575 E:1590 ||| NNS
,  ||| S:1590 E:1592 ||| ,
with  ||| S:1592 E:1597 ||| IN
PECs  ||| S:1597 E:1602 ||| JJ
being  ||| S:1602 E:1608 ||| VBG
localised  ||| S:1608 E:1618 ||| NN
within  ||| S:1618 E:1625 ||| IN
the  ||| S:1625 E:1629 ||| DT
perinuclear  ||| S:1629 E:1641 ||| JJ
area  ||| S:1641 E:1646 ||| NN
of  ||| S:1646 E:1649 ||| IN
cells ||| S:1649 E:1654 ||| NNS
.  ||| S:1654 E:1656 ||| .
Further  ||| S:1656 E:1664 ||| JJ
investigation  ||| S:1664 E:1678 ||| NN
showed  ||| S:1678 E:1685 ||| VBD
that  ||| S:1685 E:1690 ||| DT
uptake  ||| S:1690 E:1697 ||| NN
of  ||| S:1697 E:1700 ||| IN
PECs  ||| S:1700 E:1705 ||| NNP
was  ||| S:1705 E:1709 ||| VBD
unaffected  ||| S:1709 E:1720 ||| VBN
when  ||| S:1720 E:1725 ||| WRB
calcium-free  ||| S:1725 E:1738 ||| JJ
media  ||| S:1738 E:1744 ||| NNS
was  ||| S:1744 E:1748 ||| VBD
used ||| S:1748 E:1752 ||| VBN
,  ||| S:1752 E:1754 ||| ,
while  ||| S:1754 E:1760 ||| IN
presaturating  ||| S:1760 E:1774 ||| JJ
insulin  ||| S:1774 E:1782 ||| NN
receptors  ||| S:1782 E:1792 ||| VBZ
affected  ||| S:1792 E:1801 ||| VBN
the  ||| S:1801 E:1805 ||| DT
uptake  ||| S:1805 E:1812 ||| NN
of  ||| S:1812 E:1815 ||| IN
QPAA ||| S:1815 E:1819 ||| NNP
,  ||| S:1819 E:1821 ||| ,
insulin  ||| S:1821 E:1829 ||| NN
PECs ||| S:1829 E:1833 ||| NN
,  ||| S:1833 E:1835 ||| ,
but  ||| S:1835 E:1839 ||| CC
not  ||| S:1839 E:1843 ||| RB
QPAA-TBA  ||| S:1843 E:1852 ||| JJ
PECs ||| S:1852 E:1856 ||| NN
.  ||| S:1856 E:1858 ||| .
The  ||| S:1858 E:1862 ||| DT
biocompatibility  ||| S:1862 E:1879 ||| NN
of  ||| S:1879 E:1882 ||| IN
PAA  ||| S:1882 E:1886 ||| NNP
and  ||| S:1886 E:1890 ||| CC
uptake  ||| S:1890 E:1897 ||| NN
of  ||| S:1897 E:1900 ||| IN
insulin  ||| S:1900 E:1908 ||| NN
was  ||| S:1908 E:1912 ||| VBD
improved  ||| S:1912 E:1921 ||| VBN
by  ||| S:1921 E:1924 ||| IN
both  ||| S:1924 E:1929 ||| DT
thiol  ||| S:1929 E:1935 ||| NN
and  ||| S:1935 E:1939 ||| CC
quaternary  ||| S:1939 E:1950 ||| JJ
substitution ||| S:1950 E:1962 ||| NN
.  ||| S:1962 E:1964 ||| .
